乳腺癌组织中端粒酶活性的研究

目的 :研究乳腺癌组织、癌旁组织、良性乳腺病变、正常乳腺组织中的端粒酶活性 ,探讨其作为乳腺癌肿瘤标志物的可能性。方法 :采用端粒重复序列扩增法 (telomeraicrepeatamplificationprotocol ,TRAP)来检测 36例乳腺癌及其相应癌旁组织 ,12例良性乳腺病变 ,6例正常乳腺组织中的端粒酶活性。结果 :36例乳腺癌组织中 ,有 33例端粒酶表达阳性 ,其阳性率为 91 7% ,而且与肿瘤的大小 ,淋巴结的状态 ,临床分期有相关性。 36例癌旁组织中 ,有 2例端粒酶表达阳性 ,阳性率为 5 6 %。 12例良性乳腺病变中 ,仅有 1例端粒酶表达阳性 ,阳性率为 8 3%。 6例正常乳腺组织端粒酶表达均为阴性。结论 :乳腺癌组织中普遍存在端粒酶活性表达 ,端粒酶有可能成为诊断乳腺癌的肿瘤标志物。     

乳腺癌组织中端粒酶活性的研究

目的：研究乳腺癌组织、癌旁组织、良性乳腺病变、正常乳腺组织中的端粒酶活性,探讨其人微言轻乳腺癌肿瘤标志物的可能性。方法：采用端粒重复序列扩增法（telomeraic repeat amplification protocol,TRAP)来检测３６例乳腺癌及其相应癌旁组织,１２例良性乳腺病变,６例正常乳腺组织中的端粒酶活性。结果：３６例乳腺癌组织中,有３３例端粒酶表达阳性,其阳性率为９１.7%,而且与肿瘤的大小,淋巴结构状态,临床分期有相关性,３６例癌旁组织中,有２例端粒酶表达阳性,阳性率为５.6%。１２例良性乳腺病变中,仅有１例端粒酶表达阳性,阳性率为８.3%。６例正常乳腺组织端粒酶表达均为阴性。结论：乳腺癌组织中普遍存在端粒酶活性表达,端粒酶有可能成为诊断乳腺癌的肿瘤标志物。     

肝癌及癌旁组织中端粒酶检测的临床意义

目的研究端粒酶作为原发性肝细胞癌（ＨＣＣ）肿瘤标志物的可能性。方法采用ＴＲＡＰ方法检测了３３例原发性肝细胞癌及其３３例癌旁组织、４例肝转移癌及其４例癌旁组织、６例肝良性肿瘤和６例正常肝组织中的端粒酶活性。结果３３例原发性肝细胞癌组织中，有３０例端粒酶表达阳性，其阳性率为９０．９％。３３例癌旁组织中，有９例端粒酶表达阳性，其阳性率为２７．３％。４例肝转移癌端粒酶活性均阳性，４例癌旁组织中，２例端粒酶表达阳性。６例肝良性肿瘤中，仅１例端粒酶表达阳性。６例正常肝组织端粒酶表达均阴性。肝癌组织端粒酶表达与肿瘤临床病理特征无关。结论肝癌组织中普遍存在端粒酶活性表达，而良性和正常肝组织中端粒酶活性较少表达。端粒酶有可能成为诊断原发性肝细胞癌的肿瘤标志物     

乳腺癌组织中端粒酶活性的研究

目的细胞中端粒(telomere)的长度与细胞寿命的调控密切相关,端粒长度的维持需要端粒酶(telomerase)的激活,近年来的研究发现,端粒酶的激活与肿瘤的发生,发展关系密切.本文研究乳腺癌组织,癌旁组织,良性乳腺病变,正常乳腺组织中的端粒酶活性,探讨其作为乳腺癌肿瘤标志物的可能性.方法采用端粒重复序列扩增法(telomeraic repeat amplification protocol,TRAP)来检测36例乳腺癌及其相应癌旁组织,12例良性乳腺病变,6例正常乳腺组织中的端粒酶活性.结果 36例乳腺癌组织中,有33例端粒酶表达阳性,其阳性率为91.7%,而且与肿瘤的大小,淋巴结的状态,临床分期有相关性.36例癌旁组织中,有2例端粒酶表达阳性,阳性率为5.6%.12例良性乳腺病变中,仅有1例端粒酶表达阳性,阳性率为8.3%.6例正常乳腺组织端粒酶表达均为阴性.结论乳腺癌组织中普遍存在端粒酶活性表达,端粒酶有可能成为诊断乳腺癌的肿瘤标志物.     

大肠癌组织中端粒酶活性的研究

目的研究大肠癌组织及相应癌旁组织中的端粒酶活性,探讨其作为肠癌肿瘤标记物的可能性。方法采用ＴＲＡＰ方法研究了４０例大肠组织（包括３７例大肠癌,３例良性大肠疾病）和２０例相应癌旁上皮组织中的端粒酶活性表达。结果２０例癌旁上皮和３例良性疾病组织中,端粒酶活性表达均为阴性;而３７例大肠癌组织中,３５例显示端粒酶活性表达为阳性,阳性率为９４．６％。结论端粒酶是特异性较强的恶性肿瘤基因标志,有可能成为大肠癌早期诊断和治疗的理想标志物     

喉癌及癌旁组织端粒酶活性检测在喉癌手术切缘定界中的意义

目的探讨喉鳞状细胞癌、相应癌旁切缘组织的端粒酶活性表达及其在喉癌手术定界研究中的意义.方法采用多聚酶链反应-酶联免疫吸附法(PCR-ELISA)对47例喉鳞状细胞癌、21例不同距离的相应癌旁组织、20例喉炎性息肉组织的端粒酶活性进行定量检测.结果47例喉癌组织中39例端粒酶呈阳性(83%),而20例喉炎性息肉组织端粒酶均为阴性,两组具有显著性差异(P＜0.001).21例癌旁5 mm处的切缘组织中有6例端粒酶呈阳性(28.6%),但其活性水平均低于相应原发肿瘤组织.而10 mm处的切缘组织端粒酶均呈阴性,两组差异有显著性(P＜0.001).结论端粒酶在喉癌组织中有较高的表达,在不同距离的癌旁切缘组织中有不同程度的表达.喉癌及癌旁组织端粒酶活性可能作为预测喉癌浸润性的指标.可望从分子水平评估喉癌手术的切缘状态,以期为指导喉癌手术分子定界提供客观而有价值的资料.     

口腔颌面部癌及癌旁组织端粒酶检测

[目的]研究口腔颌面部癌组织及相应癌旁组织中的端粒酶活性,探讨其作为口腔颌面部癌肿瘤标志物的可行 性及其临床意义。[方法]用银染TRAP法检测32例口腔颌面 部癌组织及其相应的32例癌旁组织、4例混合瘤、4例乳头状 瘤、2例造釉细胞瘤、5例正常口腔粘膜的端粒酶活性。[结 果]32例口腔颌面部癌组织中,有30例端粒酶活性表达阳性 ,其阳性率为93.7％。32例癌旁组织中,有2例端粒酶表达阳 性,其阳性率为6.3％。4例乳头状瘤、4例混合瘤、2例造釉 细胞瘤、5例正常口腔粘膜端粒酶表达均为阴性。口腔颌面 部癌组织端粒酶活性表达与该肿瘤的临床病理特征无明显 相关性(P>0.05)。[结论]口腔颌面部癌组织中普遍存在端粒酶 活性表达,而口腔良性肿瘤和正常口腔组织中端粒酶活性 较少表达,端粒酶可作为诊断口腔颌面部癌的肿瘤标志物 。癌旁组织端粒酶活化提示有少量肿瘤细胞,应随访以证 实。     

肝癌及癌旁组织中端酶检测的临床意义

目的 研究端粒酶作为原发性肝细胞癌（ＨＣＣ）肿瘤标志物的可能性。方法 采用ＴＲＡＰ方法检测了３３例原发性肝细胞癌及其３３例癌旁组织、４例肝转移癌及其４例癌旁组织、６例肝良性肿瘤和６例正常肝组织中的端粒酶活性。结果 ３３例原发性肝细胞癌组织中,有３０例端粒酶表达阳性,其阳性率为９０．９％。３３例癌旁组织中,有９例端粒酶表达阳性,其阳性率为２７．３％。４例肝转移癌端粒酶活性均阳性,４例癌旁组织中,２例     

喉癌及癌前病变组织端粒酶活性检测

目的 探讨喉鳞状细胞癌及喉癌前病变组织的端粒酶活性表达及其在喉癌发生中的作用。方法 采用多聚酶链反应－酶联免疫吸附法（PCR－ELISA）对47例喉鳞状细胞癌组织、22例喉癌前病变组织、20例喉炎性息肉组织的端粒酶活性进行定量检测。结果 47例喉鳞癌组织中39例端粒酶呈阳性（83％）,而20例喉炎性息肉组织端粒酶均为阴性,两组具有显著性差异（P＜0．001）。22例喉癌前病变组织中有15例端粒酶表达阳性（68．2％）。结论 端粒酶在喉癌组织中有较高的表达,可作为喉癌的肿瘤标志物。在喉癌前病变组织中也有低水平的端粒酶活性表达,喉癌前病变组织端粒酶活性检测将有助于喉癌的早期发现和早期治疗。     

端粒酶活性在乳腺癌中的表达及临床意义

目的　研究乳腺癌中端粒酶活性的表达 ,探讨端粒酶活化与乳腺癌发生发展的关系及其作为乳腺癌肿瘤标志物的可能性。方法　应用TRAP 银染法及TRAP ELISA方法对 2 7例乳腺癌组织及 18例相应癌旁组织中的端粒酶活性进行了定性及定量测定。结果　在 2 7例乳腺癌组织中 ,发现有 2 3例端粒酶表达阳性 ,阳性率为 85 .2 % ;而 18例相应癌旁组织中只有 1例表达阳性 ;乳腺癌组织中的端粒酶活性 (A值 )为 0 .5 85± 0 .2 86;而相应癌旁组织则为 0 .0 95±0 .0 62 ,两者比较有显著性差异 (P <0 .0 1)。乳腺癌肿块直径≥ 2cm及淋巴结转移阳性者端粒酶活性水平显著高于 <2cm及淋巴结转移阴性者 (P <0 .0 5 ) ;而端粒酶活性与肿瘤的病理类型无明显相关性 (P >0 .0 5 )。结论　端粒酶活化在乳腺癌的发生发展中起重要作用 ,有可能成为乳腺癌早期诊断的理想肿瘤标志物。     

Telomerase activity in oral and maxillofacial tumors

Telomerase activity was measured in biopsy specimens as well as surgically resected tissues of 39 oral squamous cell carcinomas (SCCs), 22 oral leukoplakias, 13 normal oral mucosas, 12 malignant salivary gland tumors, 10 benign salivary tumors and five normal salivary gland tissues adjacent to tumors using a polymerase chain reaction (PCR)-based telomerase assay. Telomerase activity was detectable in 38.5% (5/13) of normal oral mucosa samples, 54.5% (12/22) of leukoplakia samples, 82.1% (32/39) of oral SCC samples, 83.3% (10/12) of malignant salivary gland tumor samples and 0% (0/10, 0/5) of benign salivary gland tumor and normal salivary gland samples. High-level enzyme activities were seen in 20% (3/15) of mild dysplasia specimens, 50% (2/4) of moderate-severe dysplasia specimens, 48.7% (19/39) of oral SCC tissue specimens, and no high activity was seen in the normal mucosa and hyperkeratosis specimens (P for trend, <0.001). We also analyzed the proliferative activity of dysplastic leukoplakia, oral SCC, and salivary gland tumor specimens using Ki-67 immunohistochemistry. The Ki-67 labeling indices (LI) were significantly higher in dysplastic leukoplakia and oral SCC with high telomerase activity than in dysplastic leukoplakias and oral SCC with low and negative telomerase activity (P<0.01 and P<0.05). These results indicate that telomerase activity has some correlation with the progression of multistep oral carcinogenesis with the cellular proliferation, and also indicate that telomerase may be a specific marker used to distinguish malignant salivary gland tumors from their benign counterparts.     

Telomerase activity in Indian patients with carcinomas of the aerodigestive tract.

The activation of telomerase, a ribonucleoprotein maintaining telomeric length, might represent an additional required event in the multigenetic process of tumorigenesis in human cancer. To investigate whether telomerase activity is a prerequisite or a useful indicator of malignant potential, we assayed the enzyme in squamous cell carcinomas and tried to observe any correlation with clinical staging and histopathological grading. We have studied telomerase activity in 23 samples of squamous cell carcinomas of the aerodigestive tract and in 22 corresponding samples of adjoining tissues using the telomerase repeat amplification assay. Telomerase activity was detected in 100% of the tumor samples studied. The telomerase activity increased with tumor grading, but was not statistically significant. Low levels of enzyme activity were also detected in 60.86% of the adjoining normal tissue samples. Reactivation of telomerase may play an important role in the carcinogenesis of aerodigestive tract tumors. Detection of enzyme activity in the adjoining normal tissue is suggestive of microinvasion of tumor cells and/or early activation of telomerase in the progression towards cancer, before possible pathological identification.     

E2F3在喉鳞状细胞癌中的表达及临床意义

目的：探讨喉鳞癌中E2F3的表达与临床意义,为喉鳞癌的诊断、评估及治疗寻找辅助生物学指标。方法：采用免疫组化方法检测喉鳞癌组织及癌旁正常切缘组织中E2F3表达,结合喉鳞癌各临床参数,用SPSS16.0软件包进行统计分析E2F3表达情况与喉鳞癌各临床特征之间的关系。结果：E2F3在喉鳞癌与癌旁正常切缘中的阳性表达率分别为90.44%（123/136）和27.85%（22/79）,差异具有显著统计学意义（P〈0.001）;E2F3高表达与喉鳞癌患者年龄、临床分期及分型均相关（P〈0.05）。结论：E2F3核表达可能参与喉鳞癌发生发展过程;E2F3浆表达可能贯穿于喉鳞癌发生的整体过程。     

Telomerase activity in germ cell cancers and mature teratomas.

BACKGROUND: An inverse relationship has been reported between the presence of telomerase enzymatic activity and the induction of differentiation in human tumor cell lines. Male germ cell tumors represent an attractive clinical model to assess this relationship further because high telomerase activity is present in normal germ cell progenitors and in embryonal carcinomas that can differentiate into mature teratomas. To investigate how telomerase activity and the differentiation state of germ cell tumors are related, telomerase activities and telomere lengths were measured in benign testicular tissues, germ cell cancers, and mature or immature teratomas. METHODS: By use of a modified telomeric repeat amplification protocol (TRAP) assay, telomerase activity was measured in four specimens of benign testicular tissue, in 27 germ cell cancers, in seven mature teratomas, and in one immature teratoma. Telomere lengths were measured in all specimens by restriction digestion of genomic DNA and Southern blot hybridization analysis. Associations between telomerase activity and tissue histopathology were assessed with two-sided Fisher's exact tests. RESULTS: Telomerase activity was detected in all examined germ cell cancers and in the benign testicular tissue specimens. In marked contrast, telomerase activity was not detected in any mature teratoma (P<.0001). Very long telomeres were detected in some mature teratomas, consistent with telomerase repression as a late event in teratoma formation. The immature teratoma, with malignant transformation, had high telomerase activity. CONCLUSION: Telomerase is active in germ cell cancers and repressed in mature teratomas. The absence of telomerase activity may contribute to the limited proliferative capacity of mature teratomas. These findings support the existence of an inverse relationship between telomerase activity and the differentiation state of clinical germ cell tumors.